Caspase-1 has a critical role in blood-brain barrier injury and its inhibition contributes to multifaceted repair.
Animals
Blood-Brain Barrier
/ drug effects
Caspase 1
/ metabolism
Cell Death
/ physiology
Cell Movement
/ physiology
Coculture Techniques
Dipeptides
/ pharmacology
Endothelial Cells
/ metabolism
Humans
Inflammasomes
/ metabolism
Interleukin-8
/ metabolism
Male
Mice
Pericytes
/ metabolism
para-Aminobenzoates
/ pharmacology
Adhesion
Blood-brain barrier
Caspase-1
Inflammasome
Inflammation
Paraoxon
Permeability
Transmigration
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
09 Sep 2020
09 Sep 2020
Historique:
received:
17
05
2020
accepted:
13
08
2020
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
22
7
2021
Statut:
epublish
Résumé
Excessive inflammation might activate and injure the blood-brain barrier (BBB), a common feature of many central nervous system (CNS) disorders. We previously developed an in vitro BBB injury model in which the organophosphate paraoxon (PX) affects the BBB endothelium by attenuating junctional protein expression leading to weakened barrier integrity. The objective of this study was to investigate the inflammatory cellular response at the BBB to elucidate critical pathways that might lead to effective treatment in CNS pathologies in which the BBB is compromised. We hypothesized that caspase-1, a core component of the inflammasome complex, might have important role in BBB function since accumulating evidence indicates its involvement in brain inflammation and pathophysiology. An in vitro human BBB model was employed to investigate BBB functions related to inflammation, primarily adhesion and transmigration of peripheral blood mononuclear cells (PBMCs). Caspase-1 pathway was studied by measurements of its activation state and its role in PBMCs adhesion, transmigration, and BBB permeability were investigated using the specific caspase-1 inhibitor, VX-765. Expression level of adhesion and junctional molecules and the secretion of pro-inflammatory cytokines were measured in vitro and in vivo at the BBB endothelium after exposure to PX. The potential repair effect of blocking caspase-1 and downstream molecules was evaluated by immunocytochemistry, ELISA, and Nanostring technology. PX affected the BBB in vitro by elevating the expression of the adhesion molecules E-selectin and ICAM-1 leading to increased adhesion of PBMCs to endothelial monolayer, followed by elevated transendothelial-migration which was ICAM-1 and LFA-1 dependent. Blocking caspase-8 and 9 rescued the viability of the endothelial cells but not the elevated transmigration of PBMCs. Inhibition of caspase-1, on the other hand, robustly restored all of barrier insults tested including PBMCs adhesion and transmigration, permeability, and VE-cadherin protein levels. The in vitro inflammatory response induced by PX and the role of caspase-1 in BBB injury were corroborated in vivo in isolated blood vessels from hippocampi of mice exposed to PX and treated with VX-765. These results shed light on the important role of caspase-1 in BBB insult in general and specifically in the inflamed endothelium, and suggest therapeutic potential for various CNS disorders, by targeting caspase-1 in the injured BBB.
Sections du résumé
BACKGROUND
BACKGROUND
Excessive inflammation might activate and injure the blood-brain barrier (BBB), a common feature of many central nervous system (CNS) disorders. We previously developed an in vitro BBB injury model in which the organophosphate paraoxon (PX) affects the BBB endothelium by attenuating junctional protein expression leading to weakened barrier integrity. The objective of this study was to investigate the inflammatory cellular response at the BBB to elucidate critical pathways that might lead to effective treatment in CNS pathologies in which the BBB is compromised. We hypothesized that caspase-1, a core component of the inflammasome complex, might have important role in BBB function since accumulating evidence indicates its involvement in brain inflammation and pathophysiology.
METHODS
METHODS
An in vitro human BBB model was employed to investigate BBB functions related to inflammation, primarily adhesion and transmigration of peripheral blood mononuclear cells (PBMCs). Caspase-1 pathway was studied by measurements of its activation state and its role in PBMCs adhesion, transmigration, and BBB permeability were investigated using the specific caspase-1 inhibitor, VX-765. Expression level of adhesion and junctional molecules and the secretion of pro-inflammatory cytokines were measured in vitro and in vivo at the BBB endothelium after exposure to PX. The potential repair effect of blocking caspase-1 and downstream molecules was evaluated by immunocytochemistry, ELISA, and Nanostring technology.
RESULTS
RESULTS
PX affected the BBB in vitro by elevating the expression of the adhesion molecules E-selectin and ICAM-1 leading to increased adhesion of PBMCs to endothelial monolayer, followed by elevated transendothelial-migration which was ICAM-1 and LFA-1 dependent. Blocking caspase-8 and 9 rescued the viability of the endothelial cells but not the elevated transmigration of PBMCs. Inhibition of caspase-1, on the other hand, robustly restored all of barrier insults tested including PBMCs adhesion and transmigration, permeability, and VE-cadherin protein levels. The in vitro inflammatory response induced by PX and the role of caspase-1 in BBB injury were corroborated in vivo in isolated blood vessels from hippocampi of mice exposed to PX and treated with VX-765.
CONCLUSIONS
CONCLUSIONS
These results shed light on the important role of caspase-1 in BBB insult in general and specifically in the inflamed endothelium, and suggest therapeutic potential for various CNS disorders, by targeting caspase-1 in the injured BBB.
Identifiants
pubmed: 32907600
doi: 10.1186/s12974-020-01927-w
pii: 10.1186/s12974-020-01927-w
pmc: PMC7488082
doi:
Substances chimiques
Dipeptides
0
Inflammasomes
0
Interleukin-8
0
para-Aminobenzoates
0
belnacasan
00OLE78529
Caspase 1
EC 3.4.22.36
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
267Subventions
Organisme : Defense Threat Reduction Agency
ID : 11816372
Organisme : Ministry of Science and Technology, Israel
ID : 3-13576
Références
Hum Mutat. 2013 Jan;34(1):122-31
pubmed: 22833538
Nature. 2013 Jan 31;493(7434):674-8
pubmed: 23254930
Nat Immunol. 2009 Mar;10(3):241-7
pubmed: 19221555
J Clin Invest. 1997 Jan 1;99(1):3-8
pubmed: 9011572
Nat Rev Neurosci. 2011 Nov 03;12(12):723-38
pubmed: 22048062
J Cereb Blood Flow Metab. 2005 May;25(5):593-606
pubmed: 15689955
Nat Immunol. 2005 Dec;6(12):1182-90
pubmed: 16369557
Part Fibre Toxicol. 2015 Sep 04;12:27
pubmed: 26337446
Cell. 1991 Dec 20;67(6):1033-6
pubmed: 1760836
Stroke. 2004 Oct;35(10):2378-84
pubmed: 15345801
Clin Dev Immunol. 2008;2008:384982
pubmed: 18320011
Neurobiol Dis. 2010 Jan;37(1):13-25
pubmed: 19664713
Biochem Pharmacol. 2020 May;175:113863
pubmed: 32081791
Acta Neuropathol Commun. 2019 Jan 9;7(1):6
pubmed: 30626447
Nature. 1999 Apr 22;398(6729):718-23
pubmed: 10227295
Nat Neurosci. 2007 Nov;10(11):1387-94
pubmed: 17965659
Neurotherapeutics. 2011 Apr;8(2):304-15
pubmed: 21431948
Front Cell Neurosci. 2018 Oct 16;12:359
pubmed: 30459557
J Cereb Blood Flow Metab. 2016 Oct;36(10):1668-1685
pubmed: 27486046
Exp Cell Res. 2000 Aug 25;259(1):308-13
pubmed: 10942603
Arch Toxicol. 2018 May;92(5):1767-1783
pubmed: 29623357
Toxicology. 2015 Dec 2;338:37-46
pubmed: 26435000
Front Immunol. 2019 Apr 05;10:711
pubmed: 31024547
Nat Commun. 2018 Sep 25;9(1):3916
pubmed: 30254377
Circulation. 2003 Sep 23;108(12):1520-6
pubmed: 12952850
J Allergy Clin Immunol. 2002 Nov;110(5):752-6
pubmed: 12417884
Peptides. 2003 Mar;24(3):487-501
pubmed: 12732350
J Exp Med. 1996 Oct 1;184(4):1435-47
pubmed: 8879215
Ageing Res Rev. 2004 Jan;3(1):105-20
pubmed: 15163105
Hepatology. 2009 Dec;50(6):1914-23
pubmed: 19821483
J Biol Chem. 2001 May 11;276(19):16555-60
pubmed: 11278464
Hum Exp Toxicol. 1999 Mar;18(3):174-9
pubmed: 10215108
Blood. 2009 Jun 11;113(24):6246-57
pubmed: 19211506
Int Immunopharmacol. 2001 Nov;1(12):2043-62
pubmed: 11710535
Toxicol Appl Pharmacol. 1999 Oct 1;160(1):33-42
pubmed: 10502500
J Biol Chem. 2009 Jul 10;284(28):19053-66
pubmed: 19423710
Science. 1995 Mar 31;267(5206):2000-3
pubmed: 7535475
EBioMedicine. 2019 May;43:460-472
pubmed: 31162113
J Cell Commun Signal. 2017 Sep;11(3):275-279
pubmed: 28547650
J Immunol. 2004 Nov 15;173(10):6403-8
pubmed: 15528380
Toxicol Sci. 2004 Apr;78(2):241-7
pubmed: 14976354
J Cereb Blood Flow Metab. 2016 Apr;36(4):794-807
pubmed: 26661157
Am J Pathol. 2015 Jan;185(1):17-25
pubmed: 25451151
J Cereb Blood Flow Metab. 2014 Apr;34(4):660-7
pubmed: 24424382
Circulation. 2018 Aug 28;138(9):898-912
pubmed: 29588315
J Exp Med. 2002 Jan 21;195(2):245-57
pubmed: 11805151
J Mol Med (Berl). 2016 Dec;94(12):1335-1347
pubmed: 27783111
J Toxicol Clin Toxicol. 2001;39(7):711-9
pubmed: 11778669
J Immunol. 1999 Jun 15;162(12):7322-9
pubmed: 10358182
Brain Res. 2018 Nov 15;1699:54-68
pubmed: 29981290
Brain Res. 1996 Nov 11;739(1-2):88-96
pubmed: 8955928
Neurobiol Aging. 2015 Sep;36(9):2533-43
pubmed: 26119225
Toxicol Appl Pharmacol. 1996 Nov;141(1):288-98
pubmed: 8917702
Stroke. 2002 Aug;33(8):2115-22
pubmed: 12154274
J Neurochem. 1990 May;54(5):1798-801
pubmed: 2182777
J Immunol. 2001 Jun 1;166(11):6795-801
pubmed: 11359838
Mediators Inflamm. 2018 Apr 17;2018:1549549
pubmed: 29849483
Methods Mol Biol. 2011;763:369-82
pubmed: 21874465
Epilepsy Res. 2013 Jan;103(1):2-30
pubmed: 23219031
Brain Res Mol Brain Res. 1994 Mar;22(1-4):259-67
pubmed: 8015384
Mol Pharmacol. 2006 Feb;69(2):462-70
pubmed: 16278373
J Cell Biol. 2002 Apr 29;157(3):441-53
pubmed: 11980919
J Neuroimmunol. 1998 Jun 1;86(1):20-9
pubmed: 9655469
J Neuroimmunol. 1996 Jan;64(1):37-43
pubmed: 8598388
Brain. 2000 Apr;123 ( Pt 4):698-709
pubmed: 10734001
J Cereb Blood Flow Metab. 2019 Mar;39(3):395-410
pubmed: 30565961
Nat Neurosci. 2018 Oct;21(10):1318-1331
pubmed: 30250261
Science. 1998 Jan 16;279(5349):381-4
pubmed: 9430588
Nat Rev Drug Discov. 2007 Aug;6(8):650-61
pubmed: 17667956
PLoS One. 2014 Jun 17;9(6):e99733
pubmed: 24936790
Med Res Rev. 2002 Mar;22(2):146-67
pubmed: 11857637
J Cell Mol Med. 2015 Dec;19(12):2715-27
pubmed: 26293846
Transl Stroke Res. 2011 Dec;2(4):492-516
pubmed: 22299022